Image source: Shutterstock

Highlights

 

  • Pro Medicus Ltd (ASX: PME) to buy back 10.2 million shares between 1 April 2025 and 31 March 2026.

  • The company’s share price has dropped 33% from its 19 February peak.

  • Stock buybacks reduce outstanding shares, increasing earnings per share (EPS) and potentially boosting stock value.

Pro Medicus Ltd (ASX:PME) has announced a 10.2 million share buyback, set to take place between 1 April 2025 and 31 March 2026. This move comes as the once high-flying healthcare technology stock has fallen sharply, currently trading at $198 per share, a 33% decline from its 19 February peak.

The buyback signals confidence from management, who likely see the current stock price as an opportunity to repurchase shares at a discount.

Understanding Stock Buybacks

While dividends are a common way for ASX-listed companies to return capital to shareholders, buybacks offer another effective method. A stock buyback occurs when a company repurchases its own shares from the market, reducing the number of outstanding shares.

Although buybacks are more prevalent in the United States, several ASX-listed companies, including Commonwealth Bank of Australia (ASX:CBA), Qantas Airways Ltd (ASX:QAN), and Santos Ltd (ASX:STO), have also engaged in buyback programs.

Why Companies Opt for Buybacks Over Dividends

Share buybacks provide several advantages over dividends. By reducing the total number of shares in circulation, each remaining shareholder's ownership stake increases, often leading to higher earnings per share (EPS) and an improved stock price.

Additionally, buybacks offer flexibility, allowing Pro Medicus to decide when and how many shares to repurchase within the designated timeframe. In contrast, once a dividend is declared, companies are obligated to distribute the funds.

What This Buyback Signals About Pro Medicus

Companies typically initiate buybacks when they have excess cash reserves or believe their stock is undervalued.

Pro Medicus has been a standout performer on the ASX, surging over 800% in the past five years. However, the recent sharp pullback in its share price presents a rare opportunity for the company to repurchase shares at a lower valuation.

With long-term growth trends in its favor, including an ageing population and rising demand for diagnostic imaging, Pro Medicus appears poised to continue its upward trajectory.

Pro Medicus remains one of the highest-quality companies on the ASX, boasting a 10-year revenue compound annual growth rate (CAGR) of 28% and securing long-term contracts.

The company also operates in a high-growth industry, with Fortune Business Insights projecting the U.S. diagnostic imaging services market to expand from $130.38 billion in 2023 to $206.84 billion by 2030.